Consequently, mutation rates for PIK3CA are at least 10-fold higher than PIK3CB/PIK3CD/PIK3CG in solid tumours such as breast and endometrial cancer (TCGA Research Network). This evidence concerns the gene PIK3CD and endometrial cancer.